BSH 2019 | Ublituximab, umbralisib and ibrutinib in CLL and NHL
The combination of ublituximab, umbralisib and ibrutinib was investigated in an open-label, Phase I dose escalation and expansion trial in chronic lymphocytic leukaemia or R/R B-cell non-Hodgkin lymphoma (NCT02006485). We spoke to Loretta Nastoupil, MD, MD Anderson Cancer Center, Houston, TX, about the results seen with this chemo-free triplet regimen. This interview took place at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK.
Get great new content delivered to your inboxSign up